TDM1

Phase 2Small molecule

IInstitut du Cancer de Montpellier - Val d'Aurelle

TDM1 is one of 30 small molecule programs targeting Breast Cancer. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Breast CancerNot yet recruiting

Breast CancerPhase 2

Not yet recruiting

Competition

Competitive Landscape

706 competitors in Breast Cancer

#DrugCompanyPhaseTrials

Adenocard

Astellas

Preclinical

2 2

Lexiscan

Astellas

Preclinical

1 3

TDM1

IInstitut du Cancer de Montpellier - Val d'Aurelle

Phase 2

2 4

Recombinant Human Endostatin

PPeking University Third Hospital

Preclinical

1 5

Tianeptine

Pfizer

Preclinical

1 6

Ablavar

LLantheus Medical Imaging

Preclinical

2 7

Diuretic

RReprieve Cardiovascular, Inc

Preclinical

1 8

Naltrexone/bupropion

Novo Nordisk

Preclinical

1 9

Perflutren Lipid Microsphere

IImaRx Therapeutics

Preclinical

1 10

Sertraline ODT

PPfizer's Upjohn has merged with Mylan to form Viatris Inc.

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q3 2027

Phase 2Not yet recruiting

Breast Cancer

NCT04301375

Clinical

Trials by Indication[1]

Breast Cancer2 trials

Patients With Brain Metastases From HER2-positive Breast Cancer

Completed·IInstitut du Cancer de Montpellier - Val d'Aurelle·Phase 1·NCT02135159·36 enrolled

Omission of Surgery and Sentinel Lymph Node Dissection in Clinically Low-risk HER2positive Breast Cancer With High HER2 Addiction and a Complete Response Following Standard Anti- HER2-based Neoadjuvant Therapy (ELPIS Trial)

Not yet recruiting·DDavid Garcia Cinca·Phase 2·NCT04301375·27 enrolled

Sources

References

[1]
ClinicalTrials.gov — 2 trial records for TDM1. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — TDM1 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for TDM1. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Institut du Cancer de Montpellier - Val d'Aurelle company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: IInstitut du Cancer de Montpellier - Val d'Aurelle

TDM1

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q3 2027

Trials by Indication[1]

Breast Cancer2 trials

References

Drug Info

Quick Facts

Related News